News – Page 5 – Visionary Ventures

Robert J. Dempsey recently joined TearClear, an emerging global ophthalmic pharmaceutical company with a focus on eye drops that are preserved safely prior to administering dosing, as Chief Executive Officer. Prior to this role, Mr. Dempsey held positions at Shire (Takeda, now Novartis), Bausch + Lomb, Allergan and Inspire Pharmaceuticals. What follows is a Q&A with Mr. Dempsey, where he reveals, among other things, his love of American history.

Details

Jun22020

Re-Vana Therapeutics Completes of $3.25MM Pre-Series A Financing

News, Re-VanaBy Garrett Hamontree June 2, 2020

Re-Vana Completes $3.25MM Pre-Series A Financing led by Visionary Ventures and ExSight Ventures to Support Pre-clinical Development of Sustained Release Biologic and Small Molecule Therapeutics.

Details

May262020

Tarsus Presents Positive Phase IIb Results of TP-03

News, TarsusBy Garrett Hamontree May 26, 2020

Tarsus Presents Positive Results of the Jupiter Study, a Phase 2b Randomized Controlled Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Blepharitis Due to Demodex Infestation, at AOA 2020 Virtual Meeting

Details

May202020

Elad Kedar and Jeffry Weinhuff, the CEO and Chairman of Orasis Interviewed on OIS Podcast

News, OrasisBy Garrett Hamontree May 20, 2020

Elad Kedar, CEO of Orasis Pharmaceuticals shares his strategy for successfully completing a Phase 2b clinical study in preparation of their phase 3 of CSF-1 drops for temporary correction of presbyopia. Jeffry Weinhuff from Visionary Ventures joins the conversation as Chairman of the Board to explain how he evaluated the Orasis technology and what VCs look for.

Details

May192020

Ophthalmology Investing in Orange County in Orange County Business Journal Article

News, VisionaryBy Garrett Hamontree May 19, 2020

Orange County Business Journal (OCBJ) interviews Visionary Ventures managing partner Jeffry Weinhuff and a Flying L managing partner Bill Link about investing in ophthalmology.

Details

Apr212020

Robert Dempsey the New CEO of TearClear Interviewed on OIS Podcast

News, TearClearBy Garrett Hamontree April 21, 2020

In this week’s OIS Podcast, Dr. Ehsan Sadri speaks with Bob Dempsey who just assumed the CEO role for TearClear. Let’s hear how Bob’s experience taking Xiidra to market for Shire led him to the driver’s seat for one of the most promising new drug-delivery companies.

Details

Apr162020

TearClear Completes Initial Close of $25MM Series B Financing

News, TearClearBy Garrett Hamontree April 16, 2020

TearClear Completes Initial Close of $25MM Series B Financing led by Visionary Ventures, Bluestem Capital, and Flying L. Additionally, TearClear has appointed Robert Dempsey to the CEO role. Robert Dempsey and Bill Link were interviewed by Eyewire news about the latest financing and CEO appointment.

Details

Apr102020

Jeffry Weinhuff, Visionary Managing Partner, Interviewed about Life Science Investing for the Long Haul

News, VisionaryBy Garrett Hamontree April 10, 2020

Q&A with Jeffry Weinhuff from Visionary Ventures on how life science investors view the current COVID-19 climate, what opportunities might arise, and what health care innovations are more important now more than ever.

Details

Jan82020

Tarsus Pharmaceuticals Completes $60MM Series B Financing

News, TarsusBy Garrett Hamontree January 8, 2020

Tarsus Pharmaceuticals completes $60MM Series B financing

Details

Dec122019

TearClear OIS Article

News, TearClearBy Garrett Hamontree December 12, 2019

TearClear aims to be the premier specialty pharmaceutical company assuring reliable delivery of preservative-free ophthalmic drugs from preserved multi-dose solutions.

Details